Leucovorin
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | WELLCOVORIN | — | 2026-03-09 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | LEUCOVORIN CALCIUM | — | 1987-01-30 – 1991-12-12 | fda.gov ↗ |
| Approved | US (FDA) | LEUCOVORIN CALCIUM | — | 1952-06-20 | fda.gov ↗ |
Trials 760 · started per year
Press releases naming this drug 8 releases
Evidence & citations 41 cited values
Every value below carries the sentence it was read from. 1,825 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leucovorin | “Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui...” NCT01889303 ↗1314“Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗ “Patients will be randomized to receive 5 cycles of combination chemotherapy (5-FU, adriamycin, leucovorin, cytoxan, G-CSF) either as initial therapy (preoperative) or...” NCT00001250 ↗ “Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2...” NCT02527772 ↗ “It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400...” NCT01124630 ↗ “Randomization to receive 400 mg sorafenib twice daily (sorafenib group) or 400 mg sorafenib twice daily plus HAIC (SoraHAIC group) (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2,...” PMID 31070690 ↗ Jul 2019 “The FOLFOXIRI chemotherapy regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) will be administered according to the study protocol as part of total neoadjuvant...” NCT07277842 ↗ “Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV...” NCT04084496 ↗ “The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the...” NCT03042780 ↗ “This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab...” NCT00671372 ↗ “The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil ,...” NCT05007587 ↗ |
| Known as | 5-formyl tetrahydrofolic acid | “folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion” NCT05004350 ↗ |
| Known as | 5-formyltetrahydrofolate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00877227 ↗ |
| Known as | Ca-folinate | “Leucovorin (Ca-folinate) (200 mg/m2)” NCT02578368 ↗ |
| Known as | calcium folinate | “folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle)” NCT04587128 ↗7“Folinic acid calcium salt (calcium folinate) is the bioactive metabolite of folic acid that does not require reduction by dihydrofolate reductase (DHFR).” NCT04723134 ↗ “Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.” NCT07702032 ↗ “oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)” NCT02658214 ↗ “Leucovorin 400 mg/m² (or Calcium Folinate 200 mg/m²), IV, over 120 min, D1” NCT06959693 ↗ “Drug: Leucovorin (Calcium Folinate)” NCT02720068 ↗ “Drug: Leucovorin (Calcium Folinate)” NCT07621718 ↗ “Drug: Leucovorin (Calcium Folinate)” NCT07775287 ↗ |
| Known as | calcium leucovorin | “5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab” NCT06643793 ↗1“calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15” NCT02620800 ↗ |
| Known as | calcium levofolinate | “* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan” NCT02591030 ↗1“Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.” NCT05988814 ↗ |
| Known as | Citrovorum Factor | “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗1“Leucovorin calcium, Citrovorum Factor, CF, NSC-3590” NCT00002471 ↗ |
| Known as | D/L-folinic acid | “folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid)” NCT01289821 ↗ |
| Known as | dl-leucovorin | “leucovorin \[dl-leucovorin\] 400 mg/m\^2 i.v. infusion over 90 minutes” NCT01085331 ↗1“dl leucovorin\* 400 mg/m² IV infusion over 2 hours” NCT02173990 ↗ |
| Known as | DL-LV | “dextro-levogyre (DL-LV) racemic mixture 400 mg/m²” NCT03982121 ↗ |
| Known as | Elvorin | “folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h” NCT04188145 ↗ |
| Known as | Elvorine | “Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours” NCT02352337 ↗4“* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan” NCT02591030 ↗ “Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours” NCT02827201 ↗ “* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,” NCT03959293 ↗ “Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours” NCT03186326 ↗ |
| Known as | EPIC with FUDR and Leucovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815359 ↗ |
| Known as | FOL | “FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.” NCT00959647 ↗2“mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.” NCT03250832 ↗ “Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)” NCT00551213 ↗ |
| Known as | folinic acid | “Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗312“Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, followed by fluorouracil, 425 mg/m(2) intravenous bolus...” PMID 20823433 ↗ Sep 2010 “Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗ “mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes,...” NCT03099265 ↗ “This phase II trial included patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma eligible for endoscopic resection who were treated with 3 months of chemotherapy...” PMID 35981270 ↗ Aug 2022 “The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil,...” PMID 32930387 ↗ Oct 2020 “This phase II trial tests how well fluorouracil, oxaliplatin and leucovorin calcium (folinic acid) (FOLFOX) with botensilimab and balstilimab given before surgery (neoadjuvant)...” NCT06780787 ↗ “This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in...” PMID 38672597 ↗ Apr 2024 “The regimen tested consisted of bevacizumab (5 mg/kg), folinic acid(400 mg/m²), 5-fluorouracil (2400 mg/m² for 46 h), oxaliplatin (85 mg/m²) and irinotecan (70 mg/m²...” PMID 39913183 ↗ Feb 2025 “D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over...” NCT05065801 ↗ “oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2...” NCT02226380 ↗ |
| Known as | folinic acid (FA) | “folinic acid (FA)” NCT04617457 ↗ |
| Known as | Folinic acid (FA, i.e. Leucovorin, Wyeth) | “Folinic acid (FA, i.e. Leucovorin®, Wyeth)” NCT00153998 ↗ |
| Known as | Folinic acid (leucovorin) | “Folinic acid (leucovorin)” NCT01571024 ↗1“Folinic Acid (Leucovorin)” NCT02568046 ↗ |
| Known as | Folinic acid calcium salt | “Folinic acid calcium salt (calcium folinate) is the bioactive metabolite of folic acid that does not require reduction by dihydrofolate reductase (DHFR).” NCT04723134 ↗ |
| Known as | L-folinic acid | “Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗4“folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid)” NCT01289821 ↗ “folinic acid 400mg/m2 (or L-folinic acid 200 mg/m2) over 2h” NCT07118800 ↗ “folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²)” NCT07359456 ↗ “folinic acid 400 mg/m² IV (or L-folinic acid 200 mg/m²)” NCT07437287 ↗ |
| Known as | l-leucovorin | “Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer” NCT00209625 ↗1“L-Leucovorin 200 mg/sqm iv over 2 hours, day 1” NCT02904031 ↗ |
| Known as | l-LV | “Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer” NCT00209625 ↗6“Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15” NCT02102789 ↗ “Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1” NCT03493048 ↗ “Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1” NCT04084496 ↗ “Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1” NCT04224402 ↗ “Leucovorin (LV) levogyre form (LLV) 200 mg/m²” NCT03982121 ↗ “Leucovorin(l-LV) 400 mg/m2 IV over 2 hours” NCT06153368 ↗ |
| Known as | LCV | “To study the safety and effectiveness of trimetrexate (TMTX) plus leucovorin calcium rescue (LCV) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have...” NCT00000724 ↗7“To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia...” NCT00000998 ↗ “This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone).” NCT00000730 ↗ “TMTX, in combination with leucovorin (LCV), did not cause severe toxicity in a preliminary trial.” NCT00001013 ↗ “Leucovorin (LCV) IV or PO begins 6 hours after MTX has been completed over 6 hours for 8 doses” NCT00000723 ↗ “investigational drug therapy (trimetrexate plus leucovorin calcium (TMTX / LCV))” NCT00000714 ↗ “investigational drug trimetrexate (TMTX) with leucovorin rescue (LCV)” NCT00001016 ↗ “LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin” NCT05378867 ↗ |
| Known as | leucovorin (Folina tab, TTY Biopharm, TW) | “leucovorin (Folina tab, TTY Biopharm, TW)” NCT04999332 ↗ |
| Known as | Leucovorin (Folinic Acid) | “Leucovorin (Folinic Acid)” NCT01749956 ↗1“leucovorin (FOLinic acid)” NCT01420874 ↗ |
| Known as | Leucovorin (LV) | “Leucovorin (LV)” NCT02624726 ↗1“Leucovorin (LV)” NCT02402972 ↗ |
| Known as | leucovorin calcium | “All patients receive leucovorin calcium (CF) IV once at hour 36 after initiation of MTX infusion, once every 3 hours between hours 36-48, and continuing once every 6 hours...” NCT00040690 ↗323“OBJECTIVES: I. Determine the safety, tolerability, maximum tolerated dose, and dose limiting toxicity of oral SCH 66336 with fluorouracil and leucovorin calcium in patients...” NCT00003956 ↗ “Patients received modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of...” PMID 27275632 ↗ Aug 2016 “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Patients receive irinotecan hydrochloride IV over 90 minutes and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2 (FOLFIRI).” NCT00537121 ↗ “Patients receive FOLFOX7 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1.” NCT00072553 ↗ “Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.” NCT00628810 ↗ “Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks.” NCT00023751 ↗ “Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells” NCT02047474 ↗ “During the first period of this study, an initial pharmacological assessment of fluorouracil administered intravenously along with oral leucovorin calcium is made.” NCT00001579 ↗ “Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.” NCT04083235 ↗ |
| Known as | leucovorin racemate | “leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion” NCT00101894 ↗ |
| Known as | Leucovorina | “Drug: Folinic acid/ Leucovorina” NCT07490301 ↗ |
| Known as | levofolinate | “modified folinic acid [or levofolinate], fluorouracil, and oxaliplatin regimen” PMID 37068504 ↗ Apr 2023 |
| Known as | levofolinate calcium | “Drug: Leucovorin/levofolinate calcium” NCT07814417 ↗ |
| Known as | levofolinic acid | “leucovorin calcium (CF) (or levofolinic acid) orally or IV beginning 36 hours after initiation of MTX infusion” NCT00003728 ↗ |
| Known as | LV | “LV” NCT01212822 ↗ |
| Known as | NSC-119875 | “NSC-119875 CF Leucovorin calcium” NCT00002783 ↗ |
| Known as | NSC-3590 | “5-Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, Citrovorum Factor, CF, NSC-3590.” NCT00425152 ↗6“Fluorouracil, 5-FU, NSC-19893; with Leucovorin calcium, CF, NSC-3590.” NCT00002570 ↗ “Leucovorin calcium, Citrovorum Factor, CF, NSC-3590” NCT00002471 ↗ “with Leucovorin calcium, CF, NSC-3590.” NCT00002692 ↗ “Leucovorin calcium, CF, NSC-3590” NCT00002476 ↗ “CF Leucovorin calcium, NSC-3590” NCT00002557 ↗ “CF Leucovorin, NSC-3590” NCT00002691 ↗ |
| Known as | sodium folinate | “Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate” NCT01123811 ↗ |
| Known as | USEL/Leucovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00209742 ↗ |
| Action | Inhibit | “Leucovorin is a prodrug which has to be metabolized to methylenetetrahydrofolate (mTHF) in order to increase inhibition of the target enzyme thymidylate synthase (TS).” NCT02959541 ↗ |
| Modality | Small molecule | “Calcium N-\[p-\[ [ (6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)” NCT03167177 ↗ |
| Route | Oral | “Patients also take leucovorin calcium orally three times weekly.” NCT00000643 ↗ |